INmune Bio Inc’s (INMB) Quiet Period Will Expire on March 18th

INmune Bio’s (NASDAQ:INMB) quiet period is set to end on Monday, March 18th. INmune Bio had issued 1,020,560 shares in its public offering on February 4th. The total size of the offering was $8,164,480 based on an initial share price of $8.00. During the company’s quiet period, insiders and any underwriters involved in the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

NASDAQ INMB opened at $7.51 on Wednesday. INmune Bio has a twelve month low of $7.00 and a twelve month high of $9.00.

WARNING: “INmune Bio Inc’s (INMB) Quiet Period Will Expire on March 18th” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2019/03/13/inmune-bio-incs-inmb-quiet-period-will-expire-on-march-18th.html.

INmune Bio Company Profile

INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.

See Also: What are economic reports?

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.